STAT

DECEMBER 1, 2022

STAT Washington correspondent Rachel Cohrs joins us to explain how PhRMA, the all-powerful lobbying group, lost its edge in a fight over drug-pricing negotiation. We also discuss the FDA approval of a microbiome drug for the treatment of a bowel disorder and the potential for a big acquisition of Horizon Therapeutics.

Drug Pricing 211

Drug Pricing 211

STAT

OCTOBER 8, 2024

So join us as we hoist the ever-present cup of stimulation — our choice today is coconut rum — and attack the fast-growing to-do list. The trade group, however, insisted the FDA “acted to benefit special interests, raise drug prices and deprive much of the public of access to a needed medicine.”

Compounding 255

Compounding Compounding Pharmacies Vaccines Immunity 255

STAT

OCTOBER 8, 2024

The lawsuit follows an FDA announcement last week that Lilly determined its manufacturing capacity can meet “present and projected” national demand after a sustained shortage of the drug, which Lilly sells under the brand name Mounjaro for treating diabetes and as Zepbound for weight loss.

Compounding 350

Compounding Compounding Pharmacies Diabetes Drug Pricing 350

STAT

JULY 31, 2024

After much deliberation, I prescribed a new anticoagulant to prevent the formation of blood clots in his heart, instructed him to continue using his current drugs to keep his heart rate steady, and arranged a much-needed appointment with a primary care provider. Read the rest…

Medical Schools 308

Medical Schools Hospitals Drug Pricing 308

pharmaphorum

FEBRUARY 4, 2022

The criticism is fair, as conventional assessment criteria for reimbursement and pricing decisions do not typically include comprehensive analysis of a drug’s total value beyond its clinical benefits. Link between disease rarity and drug pricing. The post How does rare disease prevalence impact drug pricing in England?

Drug Pricing 103

Drug Pricing Drug Development 103

STAT

JUNE 16, 2023

If donanemab’s similar results hold up to scrutiny (the data are limited to a press release , they’ll be presented in full at the Alzheimer’s Association International Conference in July and in a forthcoming paper), it will likely enjoy the same decision. It’s beneficial. Full approval is almost a certainty.

Drug Pricing 321

Drug Pricing 321

Express Pharma

NOVEMBER 28, 2024

However, winning in the Indian market requires a strategically thought-out India-specific strategy that accounts for the market nuances such as non-uniform payer coverage of specialty drugs, pricing schedules and varying levels of healthcare infrastructure.

Pharmaceutical Companies 105

Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 105

STAT

DECEMBER 6, 2023

The news about anti-obesity drugs keeps getting better. In November, data presented at the American Heart Association meeting added cardiovascular benefit to value in combating obesity and diabetes.

Diabetes 302

Diabetes Drug Pricing 302

STAT

JUNE 5, 2023

       The big news from the first few days is that the AstraZeneca drug Tagrisso cuts deaths in half when given to non-small cell lung cancer patients with an EGFR mutation after surgery. That means that over five years, one more patient out of every 10 would still be alive.   months, rather than 11.1

Drug Pricing 244

Drug Pricing Drug Development 244

Safe Biologics

JULY 13, 2023

On July 26th, ASBM and the Generics and Biosimilars Initiative (GaBI) hosted a webinar entitled MEDICARE DRUG PRICE NEGOTIATIONS: Impact on Healthcare Development and Patient Access to Medicines which focused on unintended consequences for patient access that may result from the implementation of the Inflation Reduction Act (IRA).

Drug Pricing 130

Drug Pricing Biosimilars Drug Development 130

pharmaphorum

JANUARY 16, 2023

Two top pharma companies have exited the UK’s voluntary medicines pricing agreement in protest at what the industry has said is a “punitive” system of revenue clawbacks, casting doubt on the future of the scheme in its present form.

Drug Pricing 69

Drug Pricing 69

NY Times

DECEMBER 6, 2021

President Biden presented a key provision from his Build Back Better bill that would take steps to combat the high costs of prescription drugs.

Drug Pricing 53

Drug Pricing 53

Safe Biologics

JUNE 12, 2023

Coming Soon: ASBM/GaBI Webinar on IRA’s Medicare Price Negotiation Provisions ASBM and the Generics and Biosimilars Initiative (GaBI) are in the final planning stages for the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA). Read the whitepaper here.

Biosimilars 130

Biosimilars Drug Pricing Compounding Drug Development 130

Drug Channels

OCTOBER 12, 2020

Informa Connect-CBI’s 6th Edition Drug Pricing Transparency Congress. November 16-17, 2020 | Virtual Event www.informaconnect.com/drug-pricing-transparency. Drug Channels Readers: View the complete agenda and register today. Be sure to use your exclusive promo DRUG30 to save $300 *.

Drug Pricing 40

Drug Pricing 40

Safe Biologics

JANUARY 10, 2023

In December, ASBM recorded the seventh and final module in its biosimilar Continuing Education (CE) Course on Biosimilars, presented with the Ohio State University College of Pharmacy. The latest module is entitled “PBMs and Payer Practices” and is presented by ASBM’s Immediate Past Chair Madelaine Feldman, MD, FACR.

Biosimilars 100

Biosimilars Drug Pricing 100

Drug Channels

MARCH 18, 2024

Informa Connect’s Life Sciences Pricing & Contracting USA May 21-23, 2024 | New Orleans Drug Channels readers save 10% with code 24DRCH10* Whether your daily focus is on Medicaid, Government Pricing, 340B, Drug Price Transparency, Commercial Contracting or Chargebacks , we have you covered!

Drug Pricing 98

Drug Pricing 98

Pharmaceutical Technology

JANUARY 31, 2023

The US omnibus bill passed in late December 2022 will give the agency greater powers to regulate accelerated approval drugs, while the Inflation Reduction Act’s lowering of drug prices will create an uncertain environment for drug developers, he said. That’s up to… all of us in aggregate.

Drug Pricing 52

Drug Pricing Biosimilars Drug Development 52

Pharma in Brief

FEBRUARY 16, 2024

The Patented Medicine Prices Review Board ( PMPRB or Board ) has released a “What We Learned” Report (the Report ), marking the next step along the path to new Guidelines. which was commissioned to facilitate consultation with stakeholders and report on the presentations and discussions.

Drug Pricing 52

Drug Pricing 52

Safe Biologics

SEPTEMBER 12, 2023

ASBM & GaBI Webinar on Medicare Price Negotiation Examines Impact on Innovation, Patient Access On July 26th, ASBM and the Generics and Biosimilars Initiative (GaBI) hosted a webinar entitled MEDICARE DRUG PRICE NEGOTIATIONS: Impact on Healthcare Development and Patient Access to Medicines. Spiegel’s segment here.

Biosimilars 130

Biosimilars Drug Pricing Drug Development 130

Safe Biologics

JULY 20, 2023

REGISTER NOW: July 26th ASBM/GaBI Webinar on IRA Medicare Price Negotiation On July 26th, ASBM and the Generics and Biosimilars Initiative (GaBI) will host the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA). REGISTER HERE. View the agenda.

Biosimilars 130

Biosimilars Drug Pricing Drug Development 130

Safe Biologics

JULY 20, 2023

REGISTER NOW: July 26th ASBM/GaBI Webinar on IRA Medicare Price Negotiation On July 26th, ASBM and the Generics and Biosimilars Initiative (GaBI) will host the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA). REGISTER HERE. View the agenda.

Biosimilars 130

Biosimilars Drug Pricing Drug Development 130

Drug Channels

OCTOBER 19, 2021

The 340B Drug Pricing Program’s explosive growth plays a crucial role in the economics of the health system specialty pharmacy channel. P.S. I'll be presenting my "State of Specialty Pharmacy 2021," live and in-person at next week's Asembia Specialty Pharmacy Summit. See below for data and details.

Specialty Pharmacies 96

Specialty Pharmacies Hospitals Drug Pricing 96

Safe Biologics

JULY 13, 2023

REGISTER NOW: July 26th ASBM/GaBI Webinar on IRA Medicare Price Negotiation On July 26th, ASBM and the Generics and Biosimilars Initiative (GaBI) will host the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA). REGISTER HERE.

Drug Pricing 100

Drug Pricing Biosimilars 100

Safe Biologics

JULY 13, 2023

REGISTER NOW: July 26th ASBM/GaBI Webinar on IRA Medicare Price Negotiation On July 26th, ASBM and the Generics and Biosimilars Initiative (GaBI) will host the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA). REGISTER HERE.

Drug Pricing 100

Drug Pricing Biosimilars 100

Safe Biologics

JUNE 12, 2023

Coming Soon: ASBM/GaBI Webinar on IRA’s Medicare Price Negotiation Provisions ASBM and the Generics and Biosimilars Initiative (GaBI) are in the final planning stages for the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA). Read the whitepaper here.

Biosimilars 100

Biosimilars Drug Pricing Compounding Drug Development 100

Safe Biologics

NOVEMBER 12, 2023

ASBM to Present at World Drug Safety Congress Americas 2023 On October 19th, ASBM Advisory Board Chair Philip Schneider will present at the World Drug Safety Congress Americas 2023 in Boston, Massachusetts. Read the new FDA’ Guidance here. Submit comments on the guidance here.

Biosimilars 130

Biosimilars Drug Pricing Packaging Labelling 130

Putting Patients First Blog

SEPTEMBER 3, 2024

Overall, while the NHC appreciates CMS’ intent to streamline the data submission process and make it more accessible, we encourage ongoing dialogue and adjustments to ensure that the process remains patient-centered, efficient, and capable of capturing the full spectrum of information necessary to inform meaningful drug price negotiations.

Drug Pricing 52

Drug Pricing Insurance Coverage and Processing Labelling Communication 52

FDA Law Blog: Biosimilars

SEPTEMBER 15, 2023

On September 18-20, Informa Connect will hold its annual #MDRPSummit in Chicago (and via livestream) to discuss the complex, ever-evolving laws and regulations in the government pricing and price reporting space. A complete agenda is available here. Hyman, Phelps & McNamara, P.C.’s

Drug Pricing 64

Drug Pricing 64

Drug Channels

OCTOBER 7, 2024

Other expert and thought leaders from within the industry are slated to present deep dive sessions, workshops and panels that will answer your most pressing questions: What are the latest legislative updates and proposed federal bills impacting PBM operations? What are the most effective strategies for spread pricing and reimbursement models?

Drug Pricing 97

Drug Pricing Biosimilars 97

Drug Channels

FEBRUARY 22, 2022

On March 15, 2022, Drug Channels Institute will release The 2022 Economic Report on U.S. drug pricing, reimbursement, and dispensing system. We are providing you with the opportunity to preorder this thoroughly updated, revised, and expanded 2022 edition at special discounted prices.

Specialty Pharmacies 96

Specialty Pharmacies Drug Pricing Biosimilars Vaccines 96

Big Molecule Watch

FEBRUARY 12, 2024

Today, the district court for the Western District of Texas granted the government’s motion to dismiss the lawsuit brought by PhRMA and other organizations challenging the Drug Price Negotiation Program of the Inflation Reduction Act. Becerra et al.

Drug Pricing 69

Drug Pricing 69

pharmaphorum

DECEMBER 7, 2022

Having recently assessed the relationship between drug price and prevalence of non-oncology rare diseases, CRA’s Life Sciences Practice team explores in greater depth the situation for these orphan drugs in France in this final article of a three-part series. Influence of ATUc programme on drug pricing.

Drug Pricing 105

Drug Pricing Drug Development 105

Safe Biologics

DECEMBER 6, 2023

Learn about ASBM’s recent educational activities surrounding IRA Medicare drug price negotiation, interchangeable biosimilars, and other key policy issues affecting patient access to medicines. McKibbin will continue in his current clinical duties at University of Pittsburgh Medical Center Altoona, PA.

Biosimilars 130

Biosimilars Packaging Labelling Drug Development 130

Drug Channels

SEPTEMBER 20, 2021

Drug Channels readers will save 10% off when they use code 21DRCH10 and register prior to October 20th.*.

Drug Pricing 93

Drug Pricing 93

Big Molecule Watch

AUGUST 25, 2023

The Inflation Reduction Act’s Medicare Drug Price Negotiation Program will kick off next week. There are reports that the White House may announce the list of selected drugs even before that deadline, on Tuesday, August 29 th. Before the IRA, the government could not set prices for any drugs covered by Medicare.

Drug Pricing 40

Drug Pricing Biosimilars Insurance Coverage and Processing Labelling 40

European Pharmaceutical Review

JANUARY 18, 2024

Market projections Leading treatments in the insomnia treatment market “The loss of patent exclusivity will allow cheaper generic versions of the DORAs to enter the [insomnia treatment] market” The company emphasised that at present, the US represents the largest insomnia market, with 81.9

Drug Pricing 98

Drug Pricing Biosimilars Compounding 98

Drug Channels

AUGUST 21, 2020

As regular readers know, I believe the 340B Drug Pricing Program needs to evolve into a more transparent, properly regulated program. I’ll be joining Jeremy during this webinar for an interactive presentation, discussion, and Q&A. This webinar will take place on September 11, 2020 (12:00 p.m. to 1:00 p.m.

Drug Pricing 52

Drug Pricing 52